Results 241 to 250 of about 317,688 (293)

Symptom experience of women with ischemia and no obstructive coronary artery disease: A mixed-methods approach. [PDF]

Am Heart J Plus
Thandra S, Dave E, Leon A, Huang J, Schwartz A, Gaignard S, Higgins M, Kimble LP, Mehta PK.   +8 more
europepmc   +1 more source

Motivational smoking cessation counselling and community‐based follow‐up after hospitalisation for vascular disease: A randomised controlled trial

Addiction, Volume 121, Issue 4, Page 957-969, April 2026.
Abstract Background and aims Evidence for motivational interviewing for smoking cessation is weak, with limited data on long‐term abstinence rates. This trial aimed to evaluate the effect of in‐hospital motivational interviewing‐based smoking cessation counselling combined with proactive referral to community‐based follow‐up on 6‐ and 12‐month ...
Karin Pleym, Elise Sverre, Harald Weedon‐Fekjær, Mohpal Singh Kahlon, Marie Stugaard, Einar Husebye, Serena Tonstad, Toril Dammen, John Munkhaugen   +8 more
wiley   +1 more source

Longitudinal analysis of psychometric properties of the Seattle Angina Questionnaire among patients who underwent coronary artery bypass grafting in Serbia. [PDF]

Popul Health Metr
Nesic I, Vukovic P, Kaitovic M, Tomic P, Ludoski M, Dotlic J, Sljivic A, Gazibara T.   +7 more
europepmc   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2661-2671, April 2026.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Efficacy and safety of Shexiang Tongxin pill for coronary slow flow in angina patients. [PDF]

NPJ Cardiovasc Health
Li N, He Z, Chen Y, Wang L, Gu Y, Wang S, Zhang Y, Fan M, Yang B, Xu J, Guo Y, Cao Y, Wang W, Liang C.   +13 more
europepmc   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3146-3154, April 2026.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller, Linoy Gabay, Oren Barak, Alena Kirzhner, Haitham Abu Khadija, Gabriel Chodick, Edi Vaisbuch, Yael Barer   +7 more
wiley   +1 more source

Design and rationale of the WARRIOR ancillary study for coronary CT angiographic analysis. [PDF]

Am Heart J
Tamarappoo B, Wolny R, Tomasino GF, Berman D, Handberg E, Pepine CJ, Lo MC, Budoff M, Shaw L, Shufelt C, Wei J, Gulati M, Merz CNB, Dey D.   +13 more
europepmc   +1 more source

Comparative effectiveness of combination therapy with SGLT‐2 inhibitors and GLP‐1 RAs compared with SGLT‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3273-3284, April 2026.
Abstract Aims To evaluate the effectiveness of combination therapy with sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) compared with continued SGLT‐2 inhibitor therapy in routine practice among individuals with type 2 diabetes.
Gregor A. Maier, Beata Hennig, Wolfgang Rathmann, Oliver Kuss   +3 more
wiley   +1 more source